Medirom mother labs executive makes additional investment in mother labs' series a financing at a pre-money valuation of jpy9 billion (as of march 13, 2025, approximately us$60 million)

Tokyo, march 13, 2025 (globe newswire) -- medirom healthcare technologies inc. (nasdaq: mrm) (the “company” or “medirom”) announces that yasuhiro hayami, chief business officer of medirom mother labs inc. (“mother labs”), a subsidiary of the company, has made a second investment in mother labs' series a financing at a pre-money valuation of jpy9 billion (as of march 13, 2025, approximately us$60 million). this new investment follows mr. hayami's initial investment in the series a financing in december 2024. mr. hayami is a committed senior executive of mother labs and shares medirom's corporate philosophy and vision as well as commitment to future growth potential.
MRM Ratings Summary
MRM Quant Ranking